Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus

References

• ChanJCMalikVJiaWDiabetes in Asia: epidemiology, risk factors, and pathophysiologyJAMA20093012129214019470990
   PubMed Web of Science ®Google Scholar
• YangWLuJWengJPrevalence of diabetes among men and women in ChinaNew Engl J Med20103621090110120335585
   PubMed Web of Science ®Google Scholar
• MisraAKhuranaLObesity and the metabolic syndrome in developing countriesJ Clin Endocrinol Metab200893S9S3018987276
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationIDF Diabetes AtlasBrussels, BelgiumInternational Diabetes Federation2013
   Google Scholar
• American Diabetes AssociationEconomic costs of diabetes in the US in 2012Diabetes Care2013361033104623468086
   PubMed Web of Science ®Google Scholar
• GarberAJHandelsmanYEinhornDDiagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical EndocrinologistsEndocr Pract20081493394618996826
   PubMedGoogle Scholar
• NathanDMDavidsonMBDeFronzoRAImpaired fasting glucose and impaired glucose tolerance: implications for careDiabetes Care20073075375917327355
   PubMed Web of Science ®Google Scholar
• GenuthSAlbertiKGBennettPFollow-up report on the diagnosis of diabetes mellitusDiabetes Care2003263160316714578255
   PubMed Web of Science ®Google Scholar
• HsuehWAOrloskiLWyneKPrediabetes: the importance of early identification and interventionPostgrad Med201012212914320675976
   PubMed Web of Science ®Google Scholar
• GrundySMPre-diabetes, metabolic syndrome, and cardiovascular riskJ Am Coll Cardiol20125963564322322078
   PubMed Web of Science ®Google Scholar
• TappRJShawJEZimmetPZAlbuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)Am J Kidney Dis20044479279815492944
   PubMed Web of Science ®Google Scholar
• PerkovicVVerdonCNinomiyaTThe relationship between proteinuria and coronary risk: a systematic review and meta-analysisPLoS Med20085e20718942886
   PubMed Web of Science ®Google Scholar
• PlantingaLCCrewsDCCoreshJPrevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetesClin J Am Soc Nephrol2010567368220338960
   PubMed Web of Science ®Google Scholar
• ZieglerDRathmannWDickhausTMeisingerCMielckAPrevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3Diabetes Care20083146446918039804
   PubMed Web of Science ®Google Scholar
• TabakAGHerderCRathmannWBrunnerEJKivimakiMPrediabetes: a high-risk state for diabetes developmentLancet20123792279229022683128
   PubMed Web of Science ®Google Scholar
• EldinWSEmaraMShokerAPrediabetes: a must to recognise disease stateInt J Clin Pract20086264264818266711
   PubMed Web of Science ®Google Scholar
• GrarupNAndersenGGene-environment interactions in the pathogenesis of type 2 diabetes and metabolismCurr Opin Clin Nutr Metab Care20071042042617563459
   PubMed Web of Science ®Google Scholar
• QiLHuFBHuGGenes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changesCurr Mol Med2008851953218781959
   PubMed Web of Science ®Google Scholar
• UusitupaMPeltonenMLindstromJTen-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study – secondary analysis of the randomized trialPloS One20094e565619479072
   PubMed Web of Science ®Google Scholar
• BrownLCMajumdarSRJohnsonJAType of antidepressant therapy and risk of type 2 diabetes in people with depressionDiabetes Res Clin Pract200879616717714823
   PubMed Web of Science ®Google Scholar
• AndersohnFSchadeRSuissaSGarbeELong-term use of antidepressants for depressive disorders and the risk of diabetes mellitusAm J Psychiatry200916659159819339356
   PubMed Web of Science ®Google Scholar
• KivimakiMHamerMBattyGDAntidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based studyDiabetes Care2010332611261620823343
   PubMed Web of Science ®Google Scholar
• KivimakiMBattyGDAntidepressant drug use and future diabetes riskDiabetologia201255101222038524
   PubMed Web of Science ®Google Scholar
• SharifABaboolalKRisk factors for new-onset diabetes after kidney transplantationNat Rev Nephrol2010641542320498675
   PubMed Web of Science ®Google Scholar
• LaneJTDagogo-JackSApproach to the patient with new-onset diabetes after transplant (NODAT)J Clin Endocrinol Metab2011963289329722058376
   PubMed Web of Science ®Google Scholar
• HalesCNBarkerDJThe thrifty phenotype hypothesisBr Med Bull20016052011809615
   PubMed Web of Science ®Google Scholar
• PinneySESimmonsRAEpigenetic mechanisms in the development of type 2 diabetesTrends Endocrinol Metabol201021223229
   PubMed Web of Science ®Google Scholar
• LehnenHZechnerUHaafTEpigenetics of gestational diabetes mellitus and offspring health: the time for action is in early stages of lifeMol Hum Reprod20131941542223515667
   PubMed Web of Science ®Google Scholar
• PrasaiMJMughalRSWheatcroftSBKearneyMTGrantPJScottEMDiurnal variation in vascular and metabolic function in diet-induced obesity: divergence of insulin resistance and loss of clock rhythmDiabetes2013621981198923382450
   PubMed Web of Science ®Google Scholar
• RichardsJGumzMLMechanism of the circadian clock in physiologyAm J Physiol. Regulatory, integrative and comparative physiology2013304R1053R1064
   PubMed Web of Science ®Google Scholar
• ShiSQAnsariTSMcGuinnessOPWassermanDHJohnsonCHCircadian disruption leads to insulin resistance and obesityCurr Biol20132337238123434278
   PubMed Web of Science ®Google Scholar
• RydenLStandlEBartnikMGuidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)Eur Heart J2007288813617220161
   PubMed Web of Science ®Google Scholar
• DrozdaJJrMesserJVSpertusJACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance ImprovementJ Am Coll Cardiol20115831633621676572
   PubMed Web of Science ®Google Scholar
• TiroshAShaiITekes-ManovaDNormal fasting plasma glucose levels and type 2 diabetes in young menN Engl J Med20053531454146216207847
   PubMed Web of Science ®Google Scholar
• DanknerRAbdul-GhaniMAGerberYChetritAWainsteinJRazIPredicting the 20-year diabetes incidence rateDiabetes200723551558
   Web of Science ®Google Scholar
• GodslandIFJeffsJAJohnstonDGLoss of beta cell function as fasting glucose increases in the non-diabetic rangeDiabetologia2004471157116615249997
   PubMed Web of Science ®Google Scholar
• ZieglerDRathmannWDickhausTMeisingerCMielckANeuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3Pain Med20091039340019207236
   PubMed Web of Science ®Google Scholar
• NicholsGAArondekarBHermanWHComplications of dysglycemia and medical costs associated with nondiabetic hyperglycemiaAm J Manag Care20081479179819067496
   PubMed Web of Science ®Google Scholar
• TriggleCRThe early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetesTimely Top Med Cardiovasc Dis200812E318392213
   PubMedGoogle Scholar
• ShawJDiagnosis of prediabetesMed Clin North Am201195341352viii21281837
   PubMed Web of Science ®Google Scholar
• QiaoQJousilahtiPErikssonJTuomilehtoJPredictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-upDiabetes Care2003262910291414514600
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMATripathyDDeFronzoRAContributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucoseDiabetes Care2006291130113916644654
   PubMed Web of Science ®Google Scholar
• DeFronzoRAAbdul-GhaniMAPreservation of beta-cell function: the key to diabetes preventionJ Clin Endocrinol Metab2011962354236621697254
   PubMed Web of Science ®Google Scholar
• StancakovaAJavorskyMKuulasmaaTHaffnerSMKuusistoJLaaksoMChanges in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish menDiabetes2009581212122119223598
   PubMed Web of Science ®Google Scholar
• FerranniniEGastaldelliAIozzoPPathophysiology of prediabetesMed Clin North Am201195327339viiviii21281836
   PubMed Web of Science ®Google Scholar
• DefronzoRABanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusDiabetes20095877379519336687
   PubMed Web of Science ®Google Scholar
• KanatMMariANortonLDistinct beta-cell defects in impaired fasting glucose and impaired glucose toleranceDiabetes20126144745322275086
   PubMed Web of Science ®Google Scholar
• FestaAWilliamsKHanleyAJHaffnerSMBeta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance testDiabetes2008571638164418332099
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, the European Diabetes Epidemiology GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteriaArch Intern Med200116139740511176766
   PubMed Web of Science ®Google Scholar
• HoergerTJHicksKASorensenSWCost-effectiveness of screening for pre-diabetes among overweight and obese US adultsDiabetes Care2007302874287917698614
   PubMed Web of Science ®Google Scholar
• Wang-SattlerRYuZHerderCNovel biomarkers for pre-diabetes identified by metabolomicsMol Sys Biology20128615
   PubMed Web of Science ®Google Scholar
• KolbergJWagenknechtLRoweMWPerformance of a multi-marker diabetes risk score on the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort6th World Congress on Prevention of Diabetes and its ComplicationsApril 8–11Dresden, German2010
   Google Scholar
• McKennaMLyssenkoVRoweMValidation of the Diabetes Risk Score, a Multi-Marker Panel that Assesses the Risk of Type 2 Diabetes: Combined Results of the Inter99 and Botnia Studies69th Scientific Sessions of the American Diabetes Association (ADA)June 5–9New Orleans, Louisiana2009
   Google Scholar
• FeskensEJVirtanenSMRasanenLDietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries StudyDiabetes Care199518110411127587845
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLindstromJErikssonJGPrevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med20013441343135011333990
   PubMed Web of Science ®Google Scholar
• CarrSMLhussierMForsterNAn evidence synthesis of qualitative and quantitative research on component intervention techniques, effectiveness, cost-effectiveness, equity and acceptability of different versions of health-related lifestyle advisor role in improving healthHealth Technol Assess201115iiiiv128421329611
   PubMed Web of Science ®Google Scholar
• SimmonsRKUnwinNGriffinSJInternational Diabetes Federation: an update of the evidence concerning the prevention of type 2 diabetesDiabetes Res Clin Pract20108714314919913319
   PubMed Web of Science ®Google Scholar
• World Health Organization [homepage on the Internet]2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseasesGenevaWHO Press2008 Available from: http://www.who.int/nmh/publications/9789241597418/enAccessed December 12, 2013
   Google Scholar
• SahaSGerdthamUGJohanssonPEconomic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseasesInt J Environ Res Public Health201073150319520948954
   PubMed Web of Science ®Google Scholar
• RadlKIanualeCBocciaSA systematic review of the cost-effectiveness of lifestyle modification as primary prevention intervention for type 2 diabetes mellitusEpidemiol Biostat Public Health201310e8846-1e8846-8
   Google Scholar
• PanXRLiGWHuYHEffects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes StudyDiabetes Care1997205375449096977
   PubMed Web of Science ®Google Scholar
• LiGZhangPWangJThe long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up studyLancet20083711783178918502303
   PubMed Web of Science ®Google Scholar
• RamachandranASnehalathaCMarySMukeshBBhaskarADVijayVThe Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia20064928929716391903
   PubMed Web of Science ®Google Scholar
• KosakaKNodaMKuzuyaTPrevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT malesDiabetes Res Clin Pract20056715216215649575
   PubMed Web of Science ®Google Scholar
• LindstromJIlanne-ParikkaPPeltonenMSustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention StudyLancet20063681673167917098085
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• CrandallJPKnowlerWCKahnSEThe prevention of type 2 diabetesNat Clin Pract Endocrinol Metab2008438239318493227
   PubMedGoogle Scholar
• LaaksonenDELindstromJLakkaTAPhysical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention studyDiabetes20055415816515616024
   PubMed Web of Science ®Google Scholar
• Salas-SalvadoJMartinez-GonzalezMABulloMRosEThe role of diet in the prevention of type 2 diabetesNutr Metabol Cardiovasc Dis201121Suppl 2B32B48
   PubMedGoogle Scholar
• DansingerMLTatsioniAWongJBChungMBalkEMMeta-analysis: the effect of dietary counseling for weight lossAnn Intern Med2007147415017606960
   PubMed Web of Science ®Google Scholar
• SchwarzPEGreavesCJLindströmJYatesTDaviesMJNonpharmacological interventions for the prevention of type 2 diabetes mellitusNat Rev Endocrinol2012836337322249519
   PubMed Web of Science ®Google Scholar
• OldridgeNBEconomic burden of physical inactivity: healthcare costs associated with cardiovascular diseaseEur J Cardiovasc Prev Rehabil20081513013918391637
   PubMed Web of Science ®Google Scholar
• BlairSNPhysical inactivity: the biggest public health problem of the 21st centuryBr J Sports Med2009431219136507
   PubMed Web of Science ®Google Scholar
• YatesTDaviesMGorelyTBullFKhuntiKEffectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trialDiabetes Care2009321404141019602539
   PubMed Web of Science ®Google Scholar
• TelfordRDLow physical activity and obesity: causes of chronic disease or simply predictors?Med Sci Sports Exerc2007391233124017762355
   PubMed Web of Science ®Google Scholar
• World Health Organization [homepage on the Internet]Global recommendations on physical activity for healthGenevaWHO Press2010 Available from: http://www.who.int/dietphysicalactivity/factsheet_recommendations/enAccessed December 12, 2013
   Google Scholar
• KnowlerWCFowlerSEHammanRFDiabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyLancet20093741677168619878986
   PubMed Web of Science ®Google Scholar
• TuomilehtoJSchwarzPLindstromJLong-term benefits from lifestyle interventions for type 2 diabetes preventionDiabetes Care201134Suppl 2S210S21421525457
   PubMedGoogle Scholar
• AltmanDGSustaining interventions in community systems: on the relationship between researchers and communitiesHealth Psychol1995145265368565927
   PubMed Web of Science ®Google Scholar
• O’TooleTPAaronKFChinMHHorowitzCTysonFCommunity-based participatory research: opportunities, challenges, and the need for a common languageJ Gen Intern Med20031859259412848844
   PubMed Web of Science ®Google Scholar
• SchwarzPEReddyPGreavesCDunbarJSchwarzJDiabetes Prevention in PracticeDresden, GermanyTUMAINI Institute for Prevention Management2010
   Google Scholar
• Finnish Diabetes AssociationProgramme for the Prevention of Type 2 Diabetes in Finland, 2003–2010Tampere, FinlandFinnish Diabetes Association2003 Available from: http://www.diabetes.fi/files/1108/Programme_for_the_Prevention_of_Type_2_Diabetes_in_Finland_2003-2010.pdfAccessed August 2, 2013
   Google Scholar
• SaaristoTMoilanenLKorpi-HyövältiELifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D)Diabetes Care2010332146215120664020
   PubMed Web of Science ®Google Scholar
• SchwarzPELindströmJKissimova-ScarbeckKThe European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) projectExp Clin Endocrinol Diabetes200811616717218350480
   PubMed Web of Science ®Google Scholar
• VermuntPWAMilderIEJWiellardFVriesJHMvan OersHAMWestertGPLifestyle counseling for type 2 diabetes risk reduction in Dutch primary care. Results of the APHRODITE study after 0.5 and 1.5 yearsDiabetes Care2011241919192521775759
   PubMedGoogle Scholar
• RosalMCBenjaminEMPekowPSLemonSCvon GoelerDOpportunities and challenges for diabetes prevention at two community health centersDiabetes Care20083124725417989311
   PubMed Web of Science ®Google Scholar
• PaulweberBValensiPLindströmJA European evidence-based guideline for the prevention of type 2 diabetesHorm Metab Res201042S3S3620391306
   PubMed Web of Science ®Google Scholar
• LindströmJNeumannASheppardKETake action to prevent diabetes: the IMAGE toolkit for the prevention of type 2 diabetes in EuropeHorm Metab Res201042S37S5520391307
   PubMed Web of Science ®Google Scholar
• PajunenPLandgrafRMuylleFQuality indicators for the prevention of type 2 diabetes in Europe: IMAGEHorm Metab Res201042S56S6320391308
   PubMed Web of Science ®Google Scholar
• UusitupaMTuomilehtoJPuskaPAre we really active in the prevention of obesity and type 2 diabetes at the community level?Nutr Metab Cardiovasc Dis20112138038921470836
   PubMed Web of Science ®Google Scholar
• AbsetzPOldenburgBHankonenNType 2 diabetes prevention in the real world: three-year results of the GOAL Lifestyle Implementation TrialDiabetes Care2009321418142019401442
   PubMed Web of Science ®Google Scholar
• AckermannRTFinchEABrizendineEZhouHMarreroDGTranslating the Diabetes Prevention Program into the community: the DEPLOY pilot studyAm J Prev Med20083535736318779029
   PubMed Web of Science ®Google Scholar
• KulzerBHermannsNGorgesDSchwarzPHaakTPrevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomesDiabetes Care2009321143114619509014
   PubMed Web of Science ®Google Scholar
• LaatikainenTDunbarJAChapmanAPrevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention ProjectBMC Public Health2007724917877832
   PubMed Web of Science ®Google Scholar
• MakrilakisKLiatisSGrammatikouSPerreaDKatsilambrosNImplementation and effectiveness of the first community lifestyle intervention programme to prevent type 2 diabetes in Greece: the DE-PLAN studyDiabet Med20102745946520536519
   PubMed Web of Science ®Google Scholar
• PennLMoffattSMWhiteMParticipants’ perspective on maintaining behavior change: a qualitative study within the European Diabetes Prevention StudyBMC Public Health2008823518616797
   PubMed Web of Science ®Google Scholar
• KronsbeinPFischerMRTolksDIMAGE: Development of a European curriculum for the training of prevention managersBr J Diabetes Vasc Dis201111163167
   Google Scholar
• CristJDEscandon-DominguezSIdentifying and recruiting Mexican American partners and sustaining community partnershipsJ Transcult Nurs20031426627112861929
   PubMedGoogle Scholar
• FosterJStanekKCross-cultural considerations in the conduct of community-based participatory researchFam Community Health200730424917149031
   PubMed Web of Science ®Google Scholar
• LaskerRDWeissESCreating partnership synergy: the critical role of community stakeholdersJ Health Hum Serv Adm20032611913915330382
   PubMedGoogle Scholar
• CaldwellCHZimmermanMAIsicheiPAForging collaborative partnerships to enhance family health: an assessment of strengths and challenges in conducting community-based researchJ Public Health Manag Pract200171912174395
   PubMedGoogle Scholar
• BryantCABrownKRMcDermottRJCommunity-based prevention marketing: organizing a community for health behavior interventionHealth Promot Pract2007815416316923844
   PubMedGoogle Scholar
• ChristopherSWattsVMcCormickAKYoungSBuilding and maintaining trust in a community-based participatory research partnershipAm J Public Health2008981398140618556605
   PubMed Web of Science ®Google Scholar
• CotterJJWellefordEAVesley-MasseyKThurstonMOCollaborative community-based research and innovationFam Community Health20032632933714528138
   PubMed Web of Science ®Google Scholar
• KaplanSACalmanNSGolubMRuddockCBillingsJFostering organizational change through a community-based initiativeHealth Promot Pract20067181S190S16760250
   PubMedGoogle Scholar
• KatzDLRepresenting your community in community-based participatory research: differences made and measuredPrev Chronic Dis20041A1215634374
   PubMedGoogle Scholar
• KellyKJVan VlaenderenHDynamics of participation in a community health projectSoc Sci Med199642123512468733194
   PubMed Web of Science ®Google Scholar
• KellyPJPractical suggestions for community interventions using participatory action researchPublic Health Nurs200522657315670327
   PubMed Web of Science ®Google Scholar
• KoneASullivanMSenturiaKDChrismanNJCiskeSJKriegerJWImproving collaboration between researchers and communitiesPublic Health Rep200011524324810968762
   PubMed Web of Science ®Google Scholar
• LantzPMViruell-FuentesEIsraelBASoftleyDGuzmanRCan communities and academia work together on public health research? Evaluation results from a community-based participatory research partnership in DetroitJ Urban Health20017849550711564852
   PubMed Web of Science ®Google Scholar
• LaskerRDWeissESBroadening participation in community problem solving: a multidisciplinary model to support collaborative practice and researchJ Urban Health2003801447 discussion 48–6012612096
   PubMed Web of Science ®Google Scholar
• MinklerMCommunity-based research partnerships: challenges and opportunitiesJ Urban Health200582ii3ii1215888635
   PubMed Web of Science ®Google Scholar
• NelsonGPancerSMHaywardKKellyRPartnerships and participation of community residents in health promotion and prevention: experiences of the highfield community enrichment project (better beginnings, better futures)J Health Psychol2004921322715018724
   PubMed Web of Science ®Google Scholar
• PintoRMMcKayMMEscobarC“You’ve gotta know the community”: minority women make recommendations about community-focused health researchWom Health20084783104
   Google Scholar
• SheltonDEstablishing the public’s trust through community-based participatory research: a case example to improve health care for a rural Hispanic communityAnnu Rev Nurs Res20082623725918709753
   PubMedGoogle Scholar
• ViswanathanMAmmermanAEngECommunity-based participatory research: assessing the evidenceEvid Rep Technol Assess (Summ)2004991815460504
   PubMedGoogle Scholar
• DehavenMJChenLTeaching medical students research while reaching the underservedFam Med20053731531715883894
   PubMed Web of Science ®Google Scholar
• CarlineJDPattersonDGCharacteristics of health professions schools, public school systems, and community-based organizations in successful partnerships to increase the numbers of underrepresented minority students entering health professions educationAcad Med20037846748212742781
   PubMed Web of Science ®Google Scholar
• WallersteinNBDuranBUsing community-based participatory research to address health disparitiesHealth Prom Pract20067312323
   PubMedGoogle Scholar
• WandersmanACommunity science: bridging the gap between science and practice with community-centered modelsAm J Community Psychol20033122724212866681
   PubMed Web of Science ®Google Scholar
• WisdomKStrategies for community participation in diabetes prevention: a Detroit experienceEthn Dis200313S3-636614552457
   PubMedGoogle Scholar
• ZambranaREThe role of Latino/Hispanic communities in health services research: strategies for a meaningful partnershipJ Med Syst1996203173289001997
   PubMedGoogle Scholar
• HorowitzCRGoldfingerJZMullerSEA model for using community-based participatory research to address the diabetes epidemic in East HarlemMt Sinai J Med200875132118306238
   PubMedGoogle Scholar
• LaverackGLabonteRA planning framework for community empowerment goals within health promotionHealth Policy Plan20001525526211012399
   PubMed Web of Science ®Google Scholar
• MathesonAHowden-ChapmanPDewKEngaging communities to reduce health inequalities: why partnership?Soc Policy J N Z2005261
   Google Scholar
• ZhouGMyersRLiYRole of AMP-activated protein kinase in mechanism of metformin actionJ Clin Invest20011081167117411602624
   PubMed Web of Science ®Google Scholar
• SalpeterSRBuckleyNSKahnJASalpeterEEMeta-analysis: metformin treatment in persons at risk for diabetes mellitusAm J Med2008121149157.e218261504
   PubMed Web of Science ®Google Scholar
• BarneaMHavivLGutmanRChapnikNMadarZFroyOMetformin affects the circadian clock and metabolic rhythms in a tissue-specific mannerBiochim Biophys Acta201218221796180622968146
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGLeiterLAThe effect of acarbose on insulin sensitivity in subjects with impaired glucose toleranceDiabetes Care199619119011938908378
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRHanefeldMKarasikALaaksoMAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialLancet20023592072207712086760
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRHanefeldMKarasikALaaksoMAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trialJAMA200329048649412876091
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRHanefeldMKarasikALaaksoMAcarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial dataDiabetologia200447969975 discussion 976–97715164169
   PubMed Web of Science ®Google Scholar
• UngerRHZhouYTLipotoxicity of beta-cells in obesity and in other causes of fatty acid spilloverDiabetes200150Suppl 1S118S12111272168
   PubMedGoogle Scholar
• HigaMZhouYTRavazzolaMBaetensDOrciLUngerRHTroglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic ratsProc Natl Acad Sci U S A199996115131151810500208
   PubMed Web of Science ®Google Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic womenDiabetes2002512796280312196473
   PubMed Web of Science ®Google Scholar
• XiangAHPetersRKKjosSLEffect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetesDiabetes20065551752216443789
   PubMed Web of Science ®Google Scholar
• DefronzoRABanerjiMBrayGAActos Now for the Prevention of Diabetes (ACT NOW) studyBMC Endocr Disord200991719640291
   PubMed Web of Science ®Google Scholar
• DeFronzoRATripathyDSchwenkeDCPioglitazone for diabetes prevention in impaired glucose toleranceN Engl J Med20113641104111521428766
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet20063681096110516997664
   PubMed Web of Science ®Google Scholar
• ZinmanBHarrisSBNeumanJLow-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled studyLancet201037610311120605202
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet20093732125213519501900
   PubMed Web of Science ®Google Scholar
• TorgersonJSHauptmanJBoldrinMNSjostromLXENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsDiabetes Care20042715516114693982
   PubMed Web of Science ®Google Scholar
• GersteinHCBoschJDagenaisGRBasal insulin and cardiovascular and other outcomes in dysglycemiaN Engl J Med201236731932822686416
   PubMed Web of Science ®Google Scholar
• PerreaultLPanQMatherKJWatsonKEHammanRFKahnSEEffect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes StudyLancet20123792243225122683134
   PubMed Web of Science ®Google Scholar
• MarinaALUtzschneiderKMWrightLAMontgomeryBKMarcovinaSMKahnSEColesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell functionDiabetes Care2012351119112522446171
   PubMed Web of Science ®Google Scholar
• HandelsmanYGoldbergRBGarveyWTColesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective studyEndocr Pract20101661762820634176
   PubMed Web of Science ®Google Scholar
• RosenstockJHernandez-TrianaEHandelsmanYMisirSJonesMRClinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetesPostgrad Med2012124142022913890
   PubMed Web of Science ®Google Scholar
• RosenstockJZinmanBDipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitusCurr Opin Endocrinol Diabetes Obes2007149810717940427
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care20073021722317259484
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabetic Med20072495596117509069
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab2007921249125517244786
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetesDiabetes2007561475148017303799
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care200831303517947341
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLHolstJJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group studyLancet200235982483011897280
   PubMed Web of Science ®Google Scholar
• AstrupARossnerSVan GaalLEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyLancet20093741606161619853906
   PubMed Web of Science ®Google Scholar
• FlintAKapitzaCHindsbergerCZdravkovicMThe once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patientsAdv Ther20112821322621340616
   PubMed Web of Science ®Google Scholar
• GuoNSunJChenHZhangHZhangZCaiDLiraglutide prevents diabetes progression in prediabetic OLETF ratsEndocr J201360152822986487
   PubMed Web of Science ®Google Scholar
• RosenstockJKlaffLJSchwartzSEffects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetesDiabetes Care2010331173117520332357
   PubMed Web of Science ®Google Scholar
• AstrupACarraroRFinerNSafety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInt J Obes201236843854
   PubMed Web of Science ®Google Scholar
• Yale UniversityThe Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults Available from: http://clinicaltrials.gov/show/NCT00845559. NLM identifier: NCT00845559Accessed December 20, 2013
   Google Scholar
• CarlssonLMPeltonenMAhlinSBariatric surgery and prevention of type 2 diabetes in Swedish obese subjectsN Engl J Med201236769570422913680
   PubMed Web of Science ®Google Scholar
• de la Cruz-MunozNMessiahSEArheartKLLopez-MitnikGLipshultzSELivingstoneABariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term resultsJ Am Coll Surg2011212505511 discussion 512–51321463779
   PubMed Web of Science ®Google Scholar
• SjoholmKAnvedenAPeltonenMEvaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish obese subjects (SOS) studyDiabetes Care2013361335134023359358
   PubMed Web of Science ®Google Scholar
• LeccesiLPanunziSDe GaetanoAEffects of transoral gastroplasty on glucose homeostasis in obese subjectsJ Clin Endocrinol Metab2013981901191023543657
   PubMed Web of Science ®Google Scholar
• LuoSLuoJCincottaAHAssociation of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamsterChronobiol Int20001715517210757461
   PubMed Web of Science ®Google Scholar
• ErminioPErgot Compounds and Brain Function: Neuroendocrine and Neuropsychiatrics AspectsGoldsteinMAdv Biochem PsychopharmacolNew YorkRaven19804162
   Google Scholar
• LuoSLiangYCincottaAHIntracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamstersNeuroendocrinology19996916016610087448
   PubMed Web of Science ®Google Scholar
• CincottaAHMeierAHSouthernLLBromocriptine alters hormone rhythms and lipid metabolism in swineAnn Nutr Metabol198933305314
   PubMed Web of Science ®Google Scholar
• CincottaAHSchillerBCMeierAHBromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratusMetabolism1991406396441865827
   PubMed Web of Science ®Google Scholar
• CincottaAHMeierAHCincottaMJrBromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetesExpert Opin Invest Drugs1999816831707
   PubMedGoogle Scholar
• CincottaAHMacEachernTAMeierAHBromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamstersAm J Physiol1993264E285E2938447396
   PubMed Web of Science ®Google Scholar
• GaddeKMAllisonDBRyanDHEffects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trialLancet20113771341135221481449
   PubMed Web of Science ®Google Scholar
• GarveyWTRyanDHLookMTwo-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension studyAm J Clin Nutr20129529730822158731
   PubMed Web of Science ®Google Scholar
• GarveyWTRyanDHHenryRPrevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-releaseDiabetes Care Epub1082013
   Web of Science ®Google Scholar
• O’NeilPMSmithSRWeissmanNJRandomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM studyObesity (Silver Spring)2012201426143622421927
   PubMed Web of Science ®Google Scholar
• SmithSRWeissmanNJAndersonCMMulticenter, placebo-controlled trial of lorcaserin for weight managementN Engl J Med201036324525620647200
   PubMed Web of Science ®Google Scholar
• FidlerMCSanchezMRaetherBA one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trialJ Clin Endocrinol Metab2011963067307721795446
   PubMed Web of Science ®Google Scholar